Cipla Ltd (CIPL.BO)

CIPL.BO on Bombay Stock Exchange

696.05INR
30 Jan 2015
Change (% chg)

Rs0.75 (+0.11%)
Prev Close
Rs695.30
Open
Rs696.00
Day's High
Rs702.20
Day's Low
Rs690.20
Volume
140,427
Avg. Vol
168,463
52-wk High
Rs711.45
52-wk Low
Rs366.70

CIPL.BO

Chart for CIPL.BO

About

Cipla Limited is a pharmaceutical company. During the fiscal year ended March 31, 2012 (fiscal 2012), it introduced a number of new drugs and formulations, such as Adgain (vital nutritional supplement for hair loss); Capnea (caffeine citrate injection and oral solution) for apnoea of prematurity in infants; Caspogin (caspofungin... (more)

Overall

Beta: 0.52
Market Cap(Mil.): Rs558,659.81
Shares Outstanding(Mil.): 802.96
Dividend: 2.00
Yield (%): 0.29

Financials

  CIPL.BO Industry Sector
P/E (TTM): 49.17 37.76 38.54
EPS (TTM): 14.15 -- --
ROI: 11.02 18.79 18.06
ROE: 11.10 19.44 18.83
Search Stocks

India court bars Cipla from selling copy of Novartis respiratory drug

MUMBAI - An Indian court has barred Indian generic drugmaker Cipla Ltd from making or selling a cheaper copy of Novartis AG's respiratory drug Onbrez domestically, citing infringement of patents held by the Swiss company.

13 Jan 2015

UPDATE 1-India court bars Cipla from selling copy of Novartis respiratory drug

MUMBAI, Jan 13 - An Indian court has barred Indian generic drugmaker Cipla Ltd from making or selling a cheaper copy of Novartis AG's respiratory drug Onbrez domestically, citing infringement of patents held by the Swiss company.

13 Jan 2015

India court bars Cipla from selling copy of Novartis respiratory drug

MUMBAI, Jan 13 - An Indian court has barred Indian generic drugmaker Cipla Ltd from making or selling a cheaper copy of Novartis AG's respiratory drug Onbrez domestically, citing infringement of patents held by the Swiss company.

13 Jan 2015

Aspen, Cipla win share of $860 million South Africa AIDS drug tender

JOHANNESBURG - South Africa will spend 10 billion rand ($860 million) between 2015 and 2017 on life-prolonging HIV/AIDS treatment drugs, health authorities said on Wednesday, as studies show the prevalence of the virus is rising.

24 Dec 2014

UPDATE 1-Aspen, Cipla win share of $860 mln S.Africa AIDS drug tender

JOHANNESBURG, Dec 24 - South Africa will spend 10 billion rand ($860 million) between 2015 and 2017 on life-prolonging HIV/AIDS treatment drugs, health authorities said on Wednesday, as studies show the prevalence of the virus is rising.

24 Dec 2014

Novartis sues India's Cipla over respiratory drug Onbrez

MUMBAI - Swiss drugmaker Novartis AG said on Wednesday it had sued India's Cipla Ltd for infringing patents covering its respiratory drug Onbrez, a month after Cipla launched a copy at a fifth of the original drug's price.

17 Dec 2014

Novartis sues India's Cipla over respiratory drug Onbrez

MUMBAI, Dec 17 - Swiss drugmaker Novartis AG said on Wednesday it had sued India's Cipla Ltd for infringing patents covering its respiratory drug Onbrez, a month after Cipla launched a copy at a fifth of the original drug's price.

17 Dec 2014

BRIEF-Meda and Cipla sue Apotex to enforce Dymista patents

* Meda and cipla sue apotex to enforce dymista patents Link to press release: http://news.cision.com/meda/r/meda-and-cipla-sue-apotex-to-enforce-dymista--patents,c9690543 Further company coverage:

03 Dec 2014

India's Cipla to market Serum Institute's paediatric vaccines in Europe

MUMBAI, Nov 20 - India's Cipla Ltd said it has agreed to market paediatric vaccines made by Serum Institute of India Ltd in Europe, in a move that marks India's fourth-largest drugmaker's entry into the vaccines space.

20 Nov 2014

UPDATE 2-India's Sun Pharma Q2 profit up 15 pct; Cipla down on slowing exports

* Sun Q2 profit up 15 pct, roughly in line with street estimates

13 Nov 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: SMC Global Securities Limited
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks